Comparative Study of Muzolimine and Furosemide in Continuous Ambulatory Peritoneal Dialysis Patients

Several authors report that patients on continuous ambulatory peritoneal dialysis (CAPD) show a residual renal function greater than those on extracorporeal treatment. The use of high-dose loop diuretics has been proposed to increase and maintain this residual renal function, thereby reducing the use of hypertonic solutions and allowing a smaller restriction in water and salt intake and, in some cases, a reduced number of daily bag changes.(1-3) Furosemide was first proposed for this usage, but muzolimine seems to be the drug of choice because, when compared with other available compounds of this class of saluretics, it exhibits a rather long plasma half life and duration of action, it seems to act from the basal and not from the luminal side of the tubule, and the drug is preponderantly eliminated following metabolic degradation in liver, so that no significant change is to be expected in cases of renal failure.(4)